KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025)

Arbutus Biopharma's Operating Leases history spans 7 years, with the latest figure at $391000.0 for Q3 2025.

  • For Q3 2025, Operating Leases fell 60.02% year-over-year to $391000.0; the TTM value through Sep 2025 reached $391000.0, down 60.02%, while the annual FY2024 figure was $806000.0, 39.99% down from the prior year.
  • Operating Leases for Q3 2025 was $391000.0 at Arbutus Biopharma, down from $575000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $2.5 million in Q1 2021 and bottomed at $391000.0 in Q3 2025.
  • The 5-year median for Operating Leases is $1.3 million (2023), against an average of $1.4 million.
  • The largest annual shift saw Operating Leases fell 13.67% in 2021 before it tumbled 60.02% in 2025.
  • A 5-year view of Operating Leases shows it stood at $2.2 million in 2021, then dropped by 18.65% to $1.8 million in 2022, then dropped by 26.01% to $1.3 million in 2023, then crashed by 39.99% to $806000.0 in 2024, then crashed by 51.49% to $391000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Operating Leases are $391000.0 (Q3 2025), $575000.0 (Q2 2025), and $626000.0 (Q1 2025).